Complete Wegovy vs Mounjaro Dose Analysis & Availability
Complete Dose Range: Wegovy Compared to Mounjaro Escalation
When evaluating Wegovy compared to Mounjaro, understanding the complete dose journey is crucial for long-term treatment planning. Wegovy follows a structured 5-dose escalation: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance from week 17 onwards. This prescription-only medicine requires careful dose progression to minimise gastrointestinal side effects whilst optimising efficacy.
Mounjaro follows a similar escalation pattern but with different dose strengths, reflecting its dual GIP + GLP-1 agonist mechanism compared to Wegovy's GLP-1-only approach. At EverydayMeds, we maintain complete stock levels of every Wegovy dose, ensuring patients never experience treatment interruptions due to pharmacy supply gaps. Our Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, supporting long-term weight management consistency.
Wegovy Compared to Mounjaro: Pricing Structure & Bundle Value
Our comprehensive pricing for Wegovy compared to Mounjaro reflects the complete treatment pathway, with single Wegovy pens starting from £79.99 (0.25mg) through £209.99 (2.4mg maintenance). The Intro Duo bundle (0.25mg & 0.5mg) costs £169.99, providing the first two months of treatment in one convenient order. New customers apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices.
Bundle pricing prioritises convenience over individual pen purchases, ensuring Reliable Supply continuity throughout your dose escalation journey. Our Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 covers weeks 5-16, whilst the Gentle Start Trio (0.25mg, 0.25mg, 0.5mg) at £269.99 supports patients requiring extended initial dosing phases. Both Wegovy and Mounjaro are available from EverydayMeds—your prescriber can help determine which treatment suits your specific clinical profile.
Clinical Evidence: Wegovy Compared to Mounjaro Trial Data
In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the STEP 1 study (Wilding et al., NEJM, 2021). The STEP programme demonstrated consistent efficacy across different patient populations, including those with type 2 diabetes achieving ~9.6% weight reduction in STEP 2.
Mounjaro's clinical programme showed different results given its dual mechanism and distinct trial populations, making direct percentage comparisons inappropriate due to varying study designs and endpoints. Both treatments require prescription-only medicine status and must be used alongside a reduced-calorie diet and increased physical activity for optimal outcomes.
How Wegovy Works When Compared to Mounjaro Mechanisms
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. This mechanism may help reduce food cravings by acting on brain appetite centres, supporting sustainable eating habit changes over time. Unlike Mounjaro's dual GIP + GLP-1 approach, Wegovy's single-pathway mechanism provides targeted appetite regulation through established GLP-1 pathways. The once-weekly injection uses Novo Nordisk's FlexTouch pen technology for consistent dosing accuracy. Clinical assessment determines individual suitability based on BMI criteria and weight-related comorbidities as per NICE TA875 guidance.
Ordering Process for Wegovy Compared to Mounjaro Options
Our streamlined ordering process covers both Wegovy and Mounjaro options through the same clinical pathway, beginning with a comprehensive 3-minute online assessment reviewed by our GPhC-registered clinical team (#9012878). Standard prescriber review takes 3 working days, with express 24-hour review available for urgent requirements. Once approved, all orders ship via next-day delivery using temperature-controlled cold-chain logistics to maintain medication stability. Payment processing includes automatic application of discount codes FIRST40 (new customers) or DOSE25 (returning customers) at checkout. Our clinical team provides ongoing support throughout your dose escalation journey, ensuring smooth transitions between strength increases.
Storage Advantages: Wegovy Compared to Mounjaro Practical Benefits
Wegovy offers significant storage flexibility compared to Mounjaro, maintaining stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration, whilst Mounjaro requires return to cold storage within 21 days. This extended room temperature stability makes Wegovy more suitable for frequent travellers or those with irregular schedules. Both treatments require initial refrigerated storage between 2-8°C before first use, with the FlexTouch pen design providing consistent dose delivery throughout the temperature range. The 6-week room temperature window supports greater treatment adherence by reducing storage-related missed doses. Dose escalation timing remains critical regardless of storage method, with mandatory progression through each strength level to optimise therapeutic outcomes.
Dose Escalation Strategy: Wegovy Compared to Mounjaro Journey Planning
Long-term treatment success when choosing Wegovy compared to Mounjaro often depends on comprehensive dose escalation planning and pharmacy continuity. Our complete stock holding eliminates common treatment disruptions caused by individual dose unavailability, supporting seamless progression from starter through maintenance phases. Many patients benefit from our Step-Up bundles that anticipate future dose requirements, reducing ordering frequency whilst ensuring treatment continuity.
The 2.4mg maintenance phase typically begins around week 17, with some patients requiring extended periods at intermediate doses based on tolerability and clinical response. Our Ultimate Stability Trio provides three consecutive months of maintenance dosing, supporting long-term weight management consistency. Clinical evidence suggests that treatment discontinuation often leads to weight regain, making uninterrupted access to maintenance doses crucial for sustained outcomes.
Expert Guidance: Wegovy Compared to Mounjaro Treatment Selection
Both Wegovy and Mounjaro represent evidence-based approaches to weight management, each with distinct mechanisms and clinical profiles suited to different patient needs. Our clinical team, registered with GPhC #9012878, provides personalised guidance on treatment selection based on individual medical history, lifestyle factors, and clinical goals. The comprehensive assessment process evaluates BMI criteria, weight-related comorbidities, and previous treatment responses to determine optimal therapy selection.
Treatment success extends beyond initial weight loss to encompass long-term maintenance and lifestyle integration, requiring ongoing clinical support and consistent medication access. EverydayMeds' complete dose availability ensures continuity regardless of which treatment your prescriber recommends, with flexible bundle options supporting various escalation timelines and maintenance requirements. Apply discount code FIRST40 for new patient pricing, or DOSE25 for returning customers, with next-day delivery ensuring rapid treatment initiation once clinically approved.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
